Spots Global Cancer Trial Database for Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Official Title:
Study ID: NCT01304303
Conditions
Solid Tumor in Advanced Stage
Study Description
Brief Summary: Phase I study of SPARC1023 alone and in combination with carboplatin
Detailed Description: Pharmacokinetic profile and dose escalation study of SPARC1023 when administered as 30-min infusion.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
SPARC Site 1, Buffalo, New York, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
